Chemotherapy plus bevacizumab vs chemoimmunotherapy for metastatic colorectal cancer: Real-world analysis

Table 4 Propensity score-adjusted multivariable cox regression analysis of prognostic factors associated with progression-free survival in the original cohort

Dependent: Survival (PFS, status PFS)		All, n (%)	HR (univariable)
Gender	Male	90 (61.2)	-
	Female	57 (38.8)	1.18 (0.20-7.13, P = 0.855)
Age (year)	≤ 60	75 (51.0)	-
	> 60	72 (49.0)	1.07 (0.68-1.69, P = 0.757)
ECOG score	0-1	135 (91.8)	-
	2	12 (8.2)	1.96 (0.95-4.04, P = 0.070)
Primary tumor location	Right colon	49 (33.3)	-
	Left colon and rectum	98 (66.7)	1.34 (0.72-2.50, P = 0.356)
No. of metastatic organs	1	88 (59.9)	-
	≥ 2	59 (40.1)	0.73 (0.08-6.57, P = 0.782)
Liver metastasis	No	64 (43.5)	-
	Yes	83 (56.5)	1.27 (0.83-1.92, P = 0.268)
Lung metastasis	No	105 (71.4)	-
	Yes	42 (28.6)	0.98 (0.61-1.60, P = 0.946)
RAS	Wild type	22 (15.0)	-
	Mutation	28 (19.0)	2.17 (1.07-4.38, P = 0.031)
	Unknown	97 (66.0)	1.76 (0.99-3.15, P = 0.056)
Group	Control group	107 (72.8)	-
	Experimental group	40 (27.2)	0.60 (0.38-0.96, P = 0.034)
PS	mean ± SD	0.3 ± 0.1	0.11 (0.00-9673.56, P = 0.702)

n = 147, events = 114, Likelihood ratio test = 18.9 on 11 df (P = 0.063). PFS: Progression-free survival; HR: Hazard ratio; ECOG: Eastern Cooperative Oncology Group; PS: Propensity score.